Breast and Ovarian Cancer Genomics
21 – 30 of 75
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Difficulties in diagnostics of lung tumours in biopsies : An interpathologist concordance study evaluating the international diagnostic guidelines
(
- Contribution to journal › Article
-
Mark
Interferon Alpha-Inducible Protein 27 Expression Is Linked to Disease Severity in Chronic Infection of Both HIV-1 and HIV-2
(
- Contribution to journal › Article
-
Mark
Ovarian Carcinoma - Early Detection and Prognostication
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Copy number signatures for early diagnosis of high-grade serous ovarian carcinoma
2022) “FUTURE PERSPECTIVES IN OVARIAN CANCER RESEARCH”(
- Contribution to conference › Poster
-
Mark
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
(
- Contribution to journal › Article
-
Mark
How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer
(
- Contribution to journal › Article
- 2021
-
Mark
A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated with Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor) : A Report of 22 Cases
(
- Contribution to journal › Article
-
Mark
Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression
(
- Contribution to journal › Article
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
(
- Contribution to journal › Article
-
Mark
Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers
(
- Contribution to journal › Article